Skip to content

The verification study of the anti-obesity effect in healthy Japanese adults: a double-blind randomized, parallel-group, controlled trial

The verification study of the anti-obesity effect in healthy Japanese adults: a double-blind randomized, parallel-group, controlled trial - The verification study of the anti-obesity effect in healthy Japanese adults

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000022085
Enrollment
60
Registered
2016-04-26
Start date
2016-04-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Duration: 12 weeks Test material: Angelica keiskei powder Dose: 2 packs a day Administration: Dissolve the test food in water or warm water, and ingested at any time Duration: 12 weeks Test mate

Sponsors

ORTHOMEDICO, Inc.
Lead Sponsor
Seishin-kai Medical Association Inc, Takara Medical Clinic.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Healthy Japanese adults 2. BMI (25 kg/m2 to less than 30 kg/m2)

Exclusion criteria

Exclusion criteria: 1. At least one previous medical history of malignant tumor, heart failure or myocardial infarction 2. Currently under the treatment for either atrial fibrillation, cardiac arrhythmia, hepatic disorder, renal disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension or other chronic diseases 3. Currently taking medicines (include herbal medicines), and/or supplements 4. Allergic to medicines or foods related to the test food of this trial 5. Pregnant, lactating, or planning to get pregnant during the trial period 6. Enrolled into other clinical trials within the last 3 months before agreeing to participate in this trial 7. Judged unsuitable for participating in this trial by physician

Design outcomes

Primary

MeasureTime frame
1. Total fat area 2. Subcutaneous fat area 3. Visceral fat area *Measuring point: at 0 week, 4 weeks, 8 weeks and 12 weeks after ingestion

Secondary

MeasureTime frame
Weight Body Mass Index (BMI) Body fat percentage Waist Circumference Adiponectin Total cholesterol HDL cholesterol LDL cholesterol Triglyceride Free fatty acid Questionnaire (Likert scale) *Measuring point: at 0 week, 4 weeks, 8 weeks and 12 weeks after ingestion

Countries

Japan

Contacts

Public ContactNaoko SUZUKI

ORTHOMEDICO, Inc. R&D Department

nao@orthomedico.jp03-3818-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026